FrancophonIA/ELRC3.0 huggingface dataset:
English: Adverse reactions by frequency
Danish: Frekvenser for bivirkninger
English: Each single use vial contains 100 mg of bevacizumab in 4 mL of concentrate.
Danish: ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hvert engangshætteglas indeholder 100 mg bevacizumab i 4 ml koncentrat.
English: (17.5 vs.14.3 months; p = 0.0609)
Danish: (17,5 vs 14,3 måneder; p =
English: Hepatic impairment
Danish: Søvnighed Hovedpine
English: The addition of bevacizumab to IFN alfa-2a significantly increased PFS and objective tumour response rate.
Danish: Den progressionsfrie overlevelse og den objektive tumorresponsrate forøgedes signifikant ved tillæg af bevacizumab til IFN alfa-2a behandlingen.
English: Exfoliative dermatitis, Dry skin, Skin discolouration
Danish: Sårhelingskomplikationerb,d Eksfoliativ dermatitis Tør hud
English: p-value Overall response rate Rate (n) p-value Overall survival* (months) Median HR (95% CI) p-value A total of 154 patients (ECOG Performance Status 0 or 1) were randomised.
Danish: # I alt blev 154 patienter (ECOG-performancestatus 0 eller 1) randomiseret.
English: This was a phase III randomised, active-controlled, open-label trial investigating bevacizumab 10 mg/kg in combination with leucovorin with 5-fluorouracil bolus and then 5-fluorouracil infusional, with IV oxaliplatin (FOLFOX-4), administered on a 2-weekly schedule in previously-treated patients (second-line) with advanced colorectal cancer.
Danish: Dette var et fase III, randomiseret, aktivt kontrolleret, ublindet studie, som undersøgte bevacizumab 10 mg/kg i kombination med leucovorin og 5-fluoruracil bolus efterfulgt af 5-fluoruracil infusion med i.v.
English: Median OS (months) Hazard ratio (95% CI) p-value
Danish: Median OS (måneder) Hazard ratio (95 % konfidensinterval) p-værdi
English: • Paclitaxel 175 mg/m2 IV over 3 hours on day 1 and topotecan 0.75 mg/m2 IV over 30 minutes on days 1-3 (q3w)
Danish: over 3 timer på dag 1 og topotecan 0,75 mg/m2 i.v.
English: Each single use vial contains 400 mg of bevacizumab in 16 mL of concentrate.
Danish: ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hvert engangshætteglas indeholder 400 mg bevacizumab i 16 ml koncentrat.
English: Paclitaxel 175 mg/m2 IV over 3 hours on day 1 and cisplatin 50 mg/m2 IV on day 1 plus bevacizumab 15 mg/kg IV on day 1 (q3w)
Danish: over 3 timer på dag 1 og cisplatin 50 mg/m i.v på dag 1 plus bevacizumab 15 mg/kg i.v.
English: Median PFS (months) Hazard ratio (95% CI)4
Danish: Median PFS (måneder) Hazard ratio (95 % konfidensinterval)4
English: (16.2 vs. 17.5 months; p = 0.3769)
Danish: (16,2 vs 17,5 måneder; p =
English: Arterial thromboembolism: An increased incidence of arterial thromboembolic reactions was observed in patients treated with bevacizumab across indications, including cerebrovascular accidents, myocardial infarction, transient ischaemic attacks, and other arterial thromboembolic reactions.
Danish: Arteriel tromboemboli: En forøget forekomst af arterielle tromboemboliske bivirkninger blev observeret hos patienter, som blev behandlet med bevacizumab, uanset indikation.
English: Prior radiation is a risk factor for GI perforation in patients treated for persistent, recurrent or metastatic cervical cancer with MVASI and all patients with GI perforation had a history of prior radiation.
Danish: Hos patienter, behandlet med MVASI for persisterende, recidiverende eller metastatisk cervixcancer, er tidligere strålebehandling en risikofaktor for gastrointestinal perforation, og alle patienter, som fik gastrointestinal perforation, havde tidligere fået strålebehandling, Behandlingen skal seponeres permanent hos patienter, som udvikler gastrointestinal perforation.
English: MVASI is also used for the treatment of adult patients with persistent, recurrent or metastatic cervical cancer.
Danish: MVASI bruges også i behandlingen af voksne patienter med vedvarende livmoderhalskræft, med livmoderhalskræft, som er kommet igen, eller med livmoderhalskræft, der har spredt sig (dannet metastaser).
English: Paclitaxel 175 mg/m2 IV over 3 hours on day 1 and cisplatin 50 mg/m2 IV on day 2 plus bevacizumab 15 mg/kg IV on day 2 (q3w); or
Danish: over 24 timer på dag 1 og cisplatin 50 mg/m2 i.v på dag 2 plus bevacizumab 15 mg/kg i.v.
English: Objective response rate (%) in patients with measurable disease
Danish: Objektiv responsrate (%) for patienter med målelig sygdom N Responsrate p-værdi < 0,0001)
English: Severe adverse reactions by frequency
Danish: Frekvens af alvorlige bivirkninger
English: Capecitabine
Danish: Oxaliplatin Capecitabin
English: (11.9 vs.14.3 months; p = 0.4825)
Danish: (11,9 vs 14,3 måneder; p =
English: a patients with measurable disease at baseline Overall survival Median (months)
Danish: Antal patienter Samlet overlevelse Median tid (måneder)
English: N Response rate
Danish: Forskel i responsrate
English: Oxaliplatin
Danish: Cellulitis
English: 130 mg/m2 IV 2 h
Danish: 130 mg/m i.v.
English: This was a phase III randomised, double-blind (for bevacizumab), clinical trial investigating bevacizumab 7.5 mg/kg in combination with oral capecitabine and IV oxaliplatin (XELOX), administered on a 3-weekly schedule; or bevacizumab 5 mg/kg in combination with leucovorin with 5-fluorouracil bolus, followed by 5-fluorouracil infusional, with IV oxaliplatin (FOLFOX-4), administered on a 2-weekly schedule.
Danish: Dette var et fase III, randomiseret, dobbeltblindet (med hensyn til bevacizumab), klinisk studie, hvori bevacizumab 7,5 mg/kg i kombination med oral capecitabin og i.v.
English: Hypoxia, Dysphoniaa
Danish: Hovedpine Dysgeusi
English: p-value (Chi-squared test)
Danish: Rate (n) p-værdi
English: AUTHORISATION
Danish: Responsrate
English: Median OS (months) Hazard ratio (95% CI)
Danish: Median OS (måneder) Hazard ratio (95 % konfidensinterval)
English: Cases of foetal abnormalities in women treated with bevacizumab alone or in combination with known embryotoxic chemotherapeutics have been observed (see section 4.6) * If specified, the frequency has been derived from clinical trial data.
Danish: Der er observeret tilfælde af anormaliteter hos fostre, hvor moderen er blevet behandlet med bevacizumab alene eller i kombination med kemoterapeutika med kendt embryotoksicitet (se pkt.
English: Leucovorin
Danish: Dyspnø
English: Trial BO17704 was a randomised, double-blind phase III trial of bevacizumab in addition to cisplatin and gemcitabine versus placebo, cisplatin and gemcitabine in patients with locally advanced (stage IIIB with supraclavicular lymph node metastases or with malignant pleural or pericardial effusion), metastatic or recurrent non-squamous NSCLC, who had not received prior chemotherapy.
Danish: Det blev udført med patienter med lokalt fremskreden (stadie IIIb med supraklaviculære lymfekirtelmetastaser eller med malignt pleural eller perikardial effusion), metastatisk eller recidiverende ikke-planocellulær NSCLC, som ikke tidligere havde fået kemoterapi.
English: This condition is usually secondary to wound healing complications, gastrointestinal perforation or fistula formation.
Danish: Der er i sjældne tilfælde rapporteret nekrotiserende fasciitis, inklusive dødelige tilfælde, hos patienter behandlet med bevacizumab; dette har som regel været sekundært til sårhelingskomplikationer, gastrointestinal perforation eller fisteldannelse.
English: CT + BV (n = 179)
Danish: Kemoterapi + bevacizumab (n = 179)
English: Pulmonary hypertensiona, Nasal septum perforationa
Danish: Pulmonal hypertensiona Næseseptumperforationa
English: Efficacy results for trial BO17704 Cisplatin/Gemcitabine + placebo
Danish: Cisplatin/Gemcitabin + placebo
English: Median OS (months) Hazard ratio (95% CI)2 p-value3
Danish: Median PFS (måneder) Hazard ratio (95 % konfidensinterval)2 p-værdi3, 4
English: Randomised patients stage III optimally debulked disease2,3
Danish: Randomiserede patienter med stadie III optimalt tumorreduceret sygdom CPP (n = 219)
English: The main secondary efficacy endpoint was progression-free survival (PFS).
Danish: Det sekundære endepunkt var progessionsfri overlevelse.
English: Hypertensiona,b Thromboembolism arteriala,b,
Danish: Tromboemboli (arteriel)a,b
English: • tiredness,
Danish: • vægttab,
English: SN
Danish: Synkope
English: Grade 3-5 reactions have been observed in up to 2.3% of patients treated with bevacizumab plus chemotherapy as compared with < 1% with chemotherapy alone (NCI-CTCAE v.3).
Danish: Dette skal ses i sammenligning med < 1 % af de patienter, der kun fik kemoterapi (NCI-CTCAE v. 3).
English: Cerebrovascular accident, Syncope, Somnolence, Headache
Danish: Knogler, led, muskler og bindevæv
English: Lethargy
Danish: Artralgi
English: Bevacizumab 10 mg/kg q 2 wk.
Danish: 7,5 mg/kg i.v.
English: Bevacizumab may impair female fertility (see sections 4.6 and 4.8).
Danish: Bevacizumab kan nedsætte fertiliteten hos kvinder (se pkt.
English: Follow-up analysis was performed with a data cut-off date of 07 March 2014. p-value displayed for descriptive purpose only.
Danish: Followup-analyse blev udført ved data cut-off 7. marts 2014.
English: Median OS (months) Hazard ratio (95% CI) (eCRF)a
Danish: Hazard ratio (95 % konfidenstinterval) (eCRF)
English: Aneurysms and artery dissections
Danish: Renal trombotisk mikroangiopatia,b Aneurismer og arterielle dissektioner
English: EGFR monoclonal antibodies in combination with bevacizumab chemotherapy regimens
Danish: Epidermal Growth Factor Receptor (EGFR)-monoklonale antistoffer i kombination med kemoterapi, som indeholder bevacizumab
English: Number of patients Overall survival Median time (months) 95% CI
Danish: Antal patienter Samlet overlevelse Median tid (måneder) 95 % konfidensinterval Hazard ratiob
English: Package size blister (PVC/PVDC/alu) 50 x 1 tablet
Danish: EU/1/08/465/015 Clopidogrel Zentiva
English: Strength Pharmaceutical Form Route of Administration Packaging
Danish: Filmovertrukket tablet
English: 10x1 tablets
Danish: 300 mg
English: These patients often do not have other treatment options.
Danish: Ofte har disse patienter ikke andre behandlingsmuligheder.
English: The recommended dose is one tablet twice a day.
Danish: Den anbefalede dosis er én tablet to gange dagligt.
English: Treatment is continued for 6 weeks, but may be extended for up to another 6 weeks if needed.
Danish: Behandlingen fortsættes i seks uger, men kan forlænges i op til yderligere seks uger, hvis det skønnes nødvendigt.
English: Tablets must not be chewed or swallowed whole.
Danish: Tabletterne må ikke tygges eller synkes hele.
English: This is a summary of the European public assessment report (EPAR) for Jorveza.
Danish: Dette dokument er et sammendrag af den europæiske offentlige vurderingsrapport (EPAR) for Jorveza.
English: Jorveza budesonide
Danish: Jorveza budesonid
English: The tablet is placed on the tongue and pressed against the roof of the mouth for around two minutes until it dissolves.
Danish: Tabletten placeres på tungen og presses derefter mod den øverste del af munden i ca. to minutter, indtil den smelter.
English: Other information about Jorveza
Danish: Andre oplysninger om Jorveza
English: What measures are being taken to ensure the safe and effective use of Jorveza?
Danish: Hvilke foranstaltninger træffes der for at sikre risikofri og effektiv anvendelse af Jorveza?
English: After 6 weeks, around 58% of the patients taking Jorveza (34 out of 59 patients) had reduced eosinophils and no symptoms or only minimal symptoms, whereas none of the 29 patients taking placebo had these effects.
Danish: Efter 6 uger havde ca. 58 % af de patienter, der fik Jorveza (34 ud af 59 patienter), en reduceret koncentration af eosinofiler og ingen eller kun meget få symptomer, mens ingen af de 29 patienter, der fik placebo, oplevede disse virkninger.
English: The European Medicines Agency decided that Jorveza's benefits are greater than its risks and recommended that it be approved for use in the EU.
Danish: Det Europæiske Lægemiddelagentur konkluderede, at fordelene ved Jorveza opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
English: Side effects with Jorveza are mainly the same as those of other similar medicines.
Danish: Bivirkningerne ved Jorveza er stort set de samme som ved lignende lægemidler.
English: Why is Jorveza approved?
Danish: Hvorfor blev Jorveza godkendt?
English: Because the number of patients with eosinophilic oesophagitis is low, the disease is considered ‘rare', and Jorveza was designated an ‘orphan medicine' (a medicine used in rare diseases) on 5 August
Danish: Da antallet af patienter med eosinofil øsofagitis er lavt, betragtes sygdommen som "sjælden", og Jorveza blev udpeget som "lægemiddel til sjældne sygdomme" den 5. august 2013.
English: The full EPAR for Jorveza can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Danish: Den fuldstændige EPAR for Jorveza findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What is Jorveza and what is it used for?
Danish: Hvad er Jorveza, og hvad anvendes det til?
English: It is not intended to provide practical advice on how to use Jorveza.
Danish: Det er ikke en praktisk vejledning i, hvordan Jorveza bør anvendes.
English: What are the risks associated with Jorveza?
Danish: Hvilke risici er der forbundet med Jorveza?
English: Jorveza is available as orodispersible tablets (1 mg).
Danish: Jorveza fås som smeltetabletter (1 mg).
English: Jorveza contains the active substance budesonide.
Danish: Jorveza indeholder det aktive stof budesonid.
English: Corticosteroids help reduce inflammation by attaching to receptors of immune cells and reducing the release of substances that are involved in the inflammation process.
Danish: Kortikosteroider medvirker til at reducere betændelse ved at binde til receptorer på immunceller, hvormed de reducerer frigivelsen af stoffer, der er involveret i betændelsesprocessen.
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Jorveza can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Danish: Sammendraget af udtalelsen fra Udvalget for Lægemidler til Sjældne Sygdomme om Jorveza findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: Jorveza was compared with placebo (a dummy treatment).
Danish: Jorveza blev sammenlignet med placebo (et uvirksomt stof).
English: For more information about treatment with Jorveza, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Danish: Hvis du ønsker yderligere oplysninger om behandling med Jorveza, kan du læse indlægssedlen (også en del af denne EPAR) eller kontakte din læge eller dit apotek.
English: The active substance in Jorveza, budesonide, is a corticosteroid medicine.
Danish: Det aktive stof i Jorveza, budesonid, er et binyrebarkhormon (kortikosteroid).
English: During this time the patient should steadily swallow the saliva with the dissolved medicine.
Danish: Imens skal patienten synke det mundvand, der dannes med den opløste medicin.
English: The most common side effects with Jorveza (which may affect up to 3 in 10 people) are fungal infections in the mouth, pharynx (throat) and oesophagus.
Danish: De hyppigste bivirkninger ved Jorveza (som optræder hos op til 3 ud af 10 patienter) er svampeinfektioner i munden, svælget og spiserøret.
English: For the full list of all side effects and restrictions with Jorveza, see the package leaflet.
Danish: Den fuldstændige liste over bivirkninger og begrænsninger ved Jorveza fremgår af indlægssedlen.
English: Jorveza was shown to be effective in one main study involving 88 adults with eosinophilic oesophagitis.
Danish: Det er påvist, at Jorveza er effektivt i én hovedundersøgelse med 88 voksne med eosinofil øsofagitis.
English: The main measure of effectiveness was the level of eosinophils in the oesophagus and improvement in symptoms.
Danish: Det primære mål for virkningen var koncentrationen af eosinofiler i spiserøret og forbedring af symptomerne.
English: For practical information about using Jorveza, patients should read the package leaflet or contact their doctor or pharmacist.
Danish: Hvis du ønsker praktisk vejledning om anvendelsen af Jorveza, kan du læse indlægssedlen eller kontakte din læge eller dit apotek.
English: Jorveza benefits patients with eosinophilic oesophagitis by improving the symptoms of the disease and reducing the excess of eosinophils.
Danish: Jorveza hjælper patienter med eosinofil øsofagitis ved at forbedre symptomerne på sygdommen og reducere koncentrationen af eosinofiler.
English: Jorveza can only be obtained with a prescription and treatment should be started by a doctor experienced with diagnosing and treating eosinophilic oesophagitis.
Danish: Jorveza udleveres kun efter recept, og behandlingen bør iværksættes af en læge med erfaring i diagnosticering og behandling af patienter med eosinofil øsofagitis.
English: Eosinophilic oesophagitis is inflammation of the oesophagus (the food-pipe that leads from the mouth to the stomach), which causes symptoms including dysphagia (difficulty swallowing) and obstruction of the oesophagus.
Danish: Eosinofil øsofagitis er betændelse i spiserøret (der går fra munden til maven), som forårsager symptomer som f.eks. synkebesvær og blokering af spiserøret.
English: How does Jorveza work?
Danish: Hvordan virker Jorveza?
English: What benefits of Jorveza have been shown in studies?
Danish: Hvilke fordele viser undersøgelserne, at der er ved Jorveza?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Jorveza have been included in the summary of product characteristics and the package leaflet.
Danish: Der er anført anbefalinger og forholdsregler i produktresuméet og indlægssedlen, som patienter og sundhedspersonale skal følge for at sikre risikofri og effektiv anvendelse af Jorveza.
English: Jorveza is a medicine used to treat adults with eosinophilic oesophagitis.
Danish: Jorveza er et lægemiddel til behandling af voksne med eosinofil øsofagitis.
English: After Jorveza dissolves in the mouth, the saliva carries it to the oesophagus where it reduces the inflammation and relieves the symptoms of eosinophilic oesophagitis.
Danish: Efter Jorveza er smeltet i munden, føres det med mundvandet til spiserøret, hvor det reducerer betændelsen og lindrer symptomerne på eosinofil øsofagitis.
English: How is Jorveza used?
Danish: Hvordan anvendes Jorveza?
English: It is caused by a large build-up of white blood cells called eosinophils in the lining of the oesophagus.
Danish: Sygdommen forårsages af en stor ophobning af eosinofiler (en type hvide blodlegemer) i spiserørets slimhinde.
English: Subcutaneous or intravenous use powder: multidose vial (glass); solvent: ampoule (glass)
Danish: Pulver: Multidosis hætteglas (glas) Solvens: Ampul (glas)
English: solvent: 10 ml (reconst.
Danish: Solvens: 10 ml (Rekonstitueret opløsning 5.000 IE/ml)
English: 50000 IU Powder and solvent for solution for injection
Danish: EU/1/97/031/019 NeoRecormon 50.000 IE Pulver og solvens til injektionsvæske, opløsning
English: Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, marketing authorisation holders in the Member States
Danish: Fortegnelse over lægemidlernes navne, lægemiddelformer, styrker, indgivelsesveje, indehavere af markedsføringstilladelser i medlemsstaterne
English: Germany Hexal Aktiengesellschaft Industriestr.
Danish: Tyskland Hexal Aktiengesellschaft Industriestr.
English: Oficina D 28230 Las Rozas (Madrid) Spain
Danish: 28230 Las Rozas (Madrid) Spain
English: 11-15 Quai Dion Bouton 92800 Puteaux France
Danish: 11-15 Quai Dion Bouton 92800 Puteaux
English: MYLAN SAS 117, allée des Parcs 69800 Saint-Priest France
Danish: Frankrig MYLAN SAS 117, allée des Parcs 69800 Saint-Priest France
English: Denmark Sandoz A/S Edvard Thomsens Vej 14 DK-2300 København S Denmark
Danish: Danmark Sandoz A/S Edvard Thomsens Vej 14 DK-2300 København S Denmark
English: Romania S.C.
Danish: Rumænien S.C.
English: 11317 Tallinn Estonia
Danish: 11317 Tallinn
English: Germany IIP - Institut für industrielle Pharmazie Forschungs- und Entwicklungsgesellschaft mbH
Danish: Tyskland IIP - Institut für industrielle Pharmazie Forschungs- und Entwicklungsgesellschaft mbH
English: Belgium Takeda Belgium Gentsesteenweg 615
Danish: Belgien Takeda Belgium Gentsesteenweg 615
English: DEMO ABEE 21st Km Athens-Lamias National Highway 14568 Kryoneri Greece
Danish: Grækenland DEMO ABEE 21st Km Athens-Lamias National Highway 14568 Kryoneri Greece
English: Lithuania UAB „SANOFI-AVENTIS LIETUVA“
Danish: Litauen UAB „SANOFI-AVENTIS LIETUVA“
English: Sanofi-Aventis Estonia OÜ Pärnu mnt 139E/2
Danish: Estland Sanofi-Aventis Estonia OÜ Pärnu mnt 139E/2
English: Remedica Ltd Aharnon Street Limassol Industrial Estate 3056 Lemesos Cyprus
Danish: Cypern Remedica Ltd Aharnon Street Limassol Industrial Estate 3056 Lemesos Cyprus
English: Romania GEROT PHARMAZEUTIKA Ges.m.b.H.
Danish: Rumænien GEROT PHARMAZEUTIKA Ges.m.b.H.
English: Arrow Generiques 26, avenue Tony Garnier 69007 Lyon
Danish: Frankrig Arrow Generiques 26, avenue Tony Garnier 69007 Lyon
English: Sweden Sanofi AB Box 30052
Danish: Sanofi AB Box 30052
English: Kampenringweg 45 D-E 2803 PE GOUDA The Netherlands
Danish: Kampenringweg 45 D-E 2803 PE GOUDA
English: 08019 Barcelona Spain
Danish: 08019 Barcelona
English: 110, Esplanade du Général de Gaulle
Danish: Frankrig TEVA SANTE 110, Esplanade du Général de Gaulle
English: Austria sanofi-aventis GmbH SATURN Tower, Vienna DC Leonard-Bernstein-Straße
Danish: Østrig sanofi-aventis GmbH SATURN Tower, Vienna DC Leonard-Bernstein-Straße
English: 15, boulevard Charles de Gaulle
Danish: Frankrig Biogaran 15, boulevard Charles de Gaulle
English: SANOFI AVENTIS, S.A. Josep Plá, 2
Danish: Spanien SANOFI AVENTIS, S.A. Josep Plá, 2
English: Denmark Sanofi-aventis Denmark A/S
Danish: Danmark Sanofi-aventis Denmark A/S
English: Sanofi-Aventis AEBE 348 Syngrou Avenue, Building A'
Danish: Grækenland Sanofi-Aventis AEBE 348 Syngrou Avenue, Building A'
English: Laboratoire AGUETTANT 1, rue Alexander Fleming 69007 Lyon
Danish: Frankrig Laboratoire AGUETTANT 1, rue Alexander Fleming 69007 Lyon
English: Centrafarm B.V. Nieuwe Donk 3 4879 AC ETTEN LEUR The Netherlands
Danish: Nieuwe Donk 3 4879 AC ETTEN LEUR The Netherlands
English: Sandoz B.V. Veluwezoom 22 1327 AH ALMERE The Netherlands
Danish: Veluwezoom 22 1327 AH ALMERE The Netherlands
English: Germany Mylan dura GmbH Wittichstr.
Danish: Tyskland Mylan dura GmbH Wittichstr.
English: Belgium Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem
Danish: Belgien Sanofi Belgium Leonardo Da Vincilaan 19 1831 Diegem
English: Germany Heumann Pharma GmbH & Co. Generica KG Südwestpark 50
Danish: Tyskland Heumann Pharma GmbH & Co. Generica KG Südwestpark 50
English: Ireland Sanofi-aventis Ireland Ltd. T/A SANOFI
Danish: Sanofi-aventis Ireland Ltd. T/A SANOFI
English: Germany Dolorgiet GmbH & Co.KG Otto-von-Guericke-Str. 1
Danish: Tyskland Dolorgiet GmbH & Co.KG Otto-von-Guericke-Str. 1
English: Germany Sanofi-Aventis Deutschland GmbH
Danish: Tyskland Sanofi-Aventis Deutschland GmbH
English: Germany 1 A Pharma GmbH Keltenring 1 + 3
Danish: Tyskland 1 A Pharma GmbH Keltenring 1 + 3
English: 49, avenue Georges Pompidou
Danish: Frankrig SANDOZ 49, avenue Georges Pompidou
English: Valproic acid Convulex gelule gastro résistante
Danish: Valproinsyre Convulex gelule gastro résistante
English: Genfarma Laboratorio, S.L.
Danish: Spanien Genfarma Laboratorio, S.L.
English: Latvia sanofi-aventis Latvia SIA Kr.Valdemara 33-8 Riga LV1010
Danish: Letland sanofi-aventis Latvia SIA Kr.Valdemara 33-8
English: Germany Stadapharm GmbH Stadastr 2-18
Danish: Tyskland Stadapharm GmbH Stadastr 2-18
English: Sanofi-Aventis Netherlands B.V.
Danish: Holland Sanofi-Aventis Netherlands B.V.
English: Belgium Mylan BVBA/SPRL Terhulpsesteenweg 6 box A 1560 Hoeilaart
Danish: Belgien Mylan BVBA/SPRL Terhulpsesteenweg 6 box A 1560 Hoeilaart
English: Ranbaxy Pharmacie Génériques
Danish: Frankrig Ranbaxy Pharmacie Génériques
English: Sanofi-Aventis Cyprus Ltd Charalambou Mouskou 14 Street
Danish: Cypern Sanofi-Aventis Cyprus Ltd Charalambou Mouskou 14